StockData
X4 Pharmaceuticals, Inc logo

X4 Pharmaceuticals, Inc (XFOR) stock

XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 3/30
$2.98−0.11 (-3.56%)

Close on Nov 18, 2026Market cap $295.46MP/E –Yield –

X4 Pharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

X4 Pharmaceuticals's revenue for the twelve months ending Sep 30, 2026 was $9.90M, up 73.7% year over year. For fiscal 2025 it was $6.50M, up 150.0% from the year before. The highest annual figure on record is $6.50M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$6.50M+150.0%
FY2024Dec 31, 2024$2.60M–
FY2023Dec 31, 2023$0–
FY2022Dec 31, 2022$0–
FY2021Dec 31, 2021$0-100.0%
FY2020Dec 31, 2020$3.00M–
FY2019Dec 31, 2019$0–
FY2018Dec 31, 2018$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$2.80M+75.0%
Q2 FY2026Jun 30, 2026$2.40M+41.2%
Q1 FY2026Mar 31, 2026$2.50M+177.8%
Q4 FY2025Dec 31, 2025$2.20M+46.7%
Q3 FY2025Sep 30, 2025$1.60M+185.7%
Q2 FY2025Jun 30, 2025$1.70M+202.0%
Q1 FY2025Mar 31, 2025$900.00K–
Q4 FY2024Dec 31, 2024$1.50M–
Q3 FY2024Sep 30, 2024$560.00K–
Q2 FY2024Jun 30, 2024$563.00K–
Q1 FY2024Mar 31, 2024$0–
Q2 FY2023Jun 30, 2023$0–
Q4 FY2021Dec 31, 2021$0–
Q3 FY2021Sep 30, 2021$0–
Q2 FY2021Jun 30, 2021$0–
Q1 FY2021Mar 31, 2021$0-100.0%
Q4 FY2020Dec 31, 2020$0–
Q3 FY2020Sep 30, 2020$0–
Q2 FY2020Jun 30, 2020$0–
Q1 FY2020Mar 31, 2020$3.00M–
Q4 FY2019Dec 31, 2019$0-100.0%
Q3 FY2019Sep 30, 2019$0–
Q2 FY2019Jun 30, 2019$0–
Q1 FY2019Mar 31, 2019$0–
Q4 FY2018Dec 31, 2018$3.50M–

More X4 Pharmaceuticals figures

See a number that looks wrong?